Premium
Development of Zinc‐Specific iCEST MRI as an Imaging Biomarker for Prostate Cancer
Author(s) -
Yuan Yue,
Wei Zhiliang,
Chu Chengyan,
Zhang Jia,
Song Xiaolei,
Walczak Piotr,
Bulte Jeff W. M.
Publication year - 2019
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201909429
Subject(s) - prostate cancer , tramp , prostate , in vivo , magnetic resonance imaging , chemistry , cancer research , zinc , lncap , pathology , biomarker , cancer , medicine , endocrinology , biology , biochemistry , radiology , microbiology and biotechnology , organic chemistry
The healthy prostate contains the highest concentration of mobile zinc in the body. As this level decreases dramatically during the initial development of prostate cancer, in vivo detection of prostate zinc content may be applied for diagnosis of prostate cancer. Using 19 F ion chemical exchange saturation transfer magnetic resonance imaging (iCEST MRI) and TF‐BAPTA as a fluorinated Zn‐binding probe with micromolar sensitivity, we show that iCEST MRI is able to differentiate between normal and malignant prostate cells with a 10‐fold difference in contrast following glucose‐stimulated zinc secretion in vitro. The iCEST signal decreased in normal prostate cells upon downregulation of the ZIP1 zinc transporter. In vivo, using an orthotopic prostate cancer mouse model and a transgenic adenocarcinoma of the mouse prostate (TRAMP) model, a gradual decrease of >300 % in iCEST contrast following the transition of normal prostate epithelial cells to cancer cells was detected.